CSL Seqirus has won a US federal $22 million contract to produce 4.8 million doses of a pre-pandemic vaccine that is matched to H5N1, the currently circulating strain of bird flu virus.
This is the fourth contract awarded by the Biomedical Advanced Research and Development Authority in response to "sustained highly pathogenic avian influenza activity", the company stated.
Dave Ross, General Manager of CSL Seqirus, commented, "we embrace pandemic preparedness as a critical part of public health protection".
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Jun 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Jun 24
